ArticleToxicology reports2025
Preclinical efficacy and safety assessments of Adult human neural stem cells (AhNSCs) for spinal cord injury.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a severe and devastating condition that leads to irreversible damage to neural tissues, creating significant medical, economic, and social challenges. The ability to differentiate into multiple neural cell types and to regulate immune response makes neural stem cells (NSC) a promising strategy for treating SCI. In this study, we investigated the therapeutic potential, safety profile, and tumorigenic risk of intrathecally transplanted adult human neural stem cells (AhNSCs) produced under clinical-grade standards in a Good Manufacturing Practice (GMP) facility, in rat SCI models, thereby laying the foundation for future clinical trials. Functional tests, including the Basso, Beattie, and Bresnahan (BBB) locomotor rating, rotarod, and von Frey tests, showed significant improvements in motor function and mechanical sensitivity in rats with SCI. Histological analysis revealed reduced tissue loss, glial scar formation, and increased axonal regeneration. Biodistribution studies indicated that the transplanted AhNSCs are primarily localized within the spinal cord, with minimal systemic distribution. Toxicity studies found no significant adverse effects, suggesting a favorable safety profile. Long-term tumorigenicity studies reported no treatment-related deaths or signs of tumor formation in either gender. In conclusion, the study demonstrates that AhNSCs offer promising therapeutic potential for treating SCI, contributing to improved motor function and sensory recovery. These findings support further investigation and potential clinical applications of AhNSCs for treating SCI and related neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.